Aerska, Inc.

Aerska, Inc. is a US-based biotechnology company specializing in RNA medicines targeting neurological diseases through innovative RNA interference technologies. Aerska, Inc. was founded in Wilmington, US in 2025 by Jack O'Meara, Stuart Milstein, and David Hardwicke, focusing on the development of RNA medicines for brain-related diseases.

In February 2026, Aerska, Inc. raised USD 39 million in series A funding co-led by returning investors Age1 and EQT Life Sciences, with participation from Iaso Ventures. Lingotto Investment Management LLP, Backed VC, Saras Capital, BlueYard Capital, Norrsken VC, Speedinvest and Ada Ventures also participated in the round. Aerska specializes in developing next-generation RNA medicines designed to treat neurological diseases.

The company's core offerings utilize RNA interference (RNAi) technologies for targeted delivery of therapeutic RNA to the central nervous system, with applications for Alzheimer's disease and other neurodegenerative conditions. Aerska's solutions cater to healthcare providers, pharmaceutical firms, and research institutions, focusing on enhancing patient outcomes through precision medicine across North America, Europe, and parts of Asia. Aerska's revenue model is built on partnerships with pharmaceutical companies and research institutions in neurological research. Revenue is generated through milestone payments associated with clinical trial successes and potential licensing fees for proprietary delivery systems.

Additionally, revenue may come from research agreements where clients, including biotech firms and academic institutions, compensate Aerska for access to its innovative technologies. The company plans to use the February 2026 funding to develop its antibody-oligo conjugate platform, advance its brain shuttle technology, and move systemically delivered RNA interference treatments for neurological diseases toward clinical testing.